Literature DB >> 2150320

Enhancement of S-100 beta protein in blood of patients with Down's syndrome.

K Kato1, F Suzuki, N Kurobe, K Okajima, N Ogasawara, M Nagaya, T Yamanaka.   

Abstract

The human gene encoding the beta subunit of S-100 protein (S-100 beta) was mapped on chromosome 21. In order to confirm the expression of gene-dosage effect of S-100 beta in patients with Down's syndrome (DS), concentrations of immunoreactive S-100 alpha and S-100 beta proteins were determined in the blood plasma and lymphocytes fraction of the patients and control subjects. Cu/Zn-superoxide dismutase (SOD), a protein that is known to show the gene-dosage effect on the trisomy of chromosome 21, also was immunoassayed in the same blood samples as control proteins. In blood plasma, S-100 beta protein as well as Cu/Zn SOD was enhanced (P less than 0.001) in the patients (160 +/- 70 pg S-100 beta/ml and 87 +/- 83 ng SOD/ml, N = 44) as compared with control individuals (76 +/- 25 pg/ml, and 18 +/- 11 ng/ml, respectively, N = 28). However, concentrations of S-100 alpha in blood plasma of DS patients were similar to those of normal subjects. Concentrations of S-100 beta in lymphocyte fractions of DS patients (24.7 +/- 10.9 ng/mg protein) were also higher (P less than 0.001) than those of control subjects (10.1 +/- 5.8 ng/mg protein). These results indicate that gene-dosage effect of S-100 beta levels are expressed in DS patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2150320     DOI: 10.1007/bf02876918

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  32 in total

1.  One half of the CD11b+ human peripheral blood T lymphocytes coexpresses the S-100 protein.

Authors:  C Ferrari; P Sansoni; G Rowden; G C Manara; C Torresani; G De Panfilis
Journal:  Clin Exp Immunol       Date:  1988-06       Impact factor: 4.330

2.  A rapid and sensitive enzyme immunoassay for Cu/Zn superoxide dismutase with polyclonal and monoclonal antibodies.

Authors:  T Porstmann; R Wietschke; H Schmechta; R Grunow; B Porstmann; R Bleiber; M Pergande; S Stachat; R von Baehr
Journal:  Clin Chim Acta       Date:  1988-01-15       Impact factor: 3.786

3.  Synthesis and expression of a gene coding for the calcium-modulated protein S100 beta and designed for cassette-based, site-directed mutagenesis.

Authors:  L J Van Eldik; J L Staecker; F Winningham-Major
Journal:  J Biol Chem       Date:  1988-06-05       Impact factor: 5.157

4.  Evaluation of the internationally standardized method for haemoglobinometry.

Authors:  T Matsubara; S Shibata
Journal:  Clin Chim Acta       Date:  1969-03       Impact factor: 3.786

5.  S-100 modulates Ca2+-independent phosphorylation of an endogenous protein (Mr = 19K) in brain.

Authors:  D F Qi; J F Kuo
Journal:  J Neurochem       Date:  1984-07       Impact factor: 5.372

6.  The amino-acid sequence of S-100 protein (PAP I-b protein) and its relation to the calcium-binding proteins.

Authors:  T Isobe; T Okuyama
Journal:  Eur J Biochem       Date:  1978-09-01

7.  Sensitive enzyme immunoassay for human Cu/Zn superoxide dismutase.

Authors:  N Kurobe; F Suzuki; K Okajima; K Kato
Journal:  Clin Chim Acta       Date:  1990-01-31       Impact factor: 3.786

8.  S-100 proteins and microtubules: analysis of the effects of rat brain S-100 (S-100b) and ox brain S-100a0, S-100a and S-100b on microtubule assembly-disassembly.

Authors:  R Donato; T Isobe; T Okuyama
Journal:  FEBS Lett       Date:  1985-07-01       Impact factor: 4.124

9.  S-100 beta positive human T lymphocytes: their characteristics and behavior under normal and pathologic conditions.

Authors:  K Takahashi; T Yoshino; K Hayashi; H Sonobe; Y Ohtsuki
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

10.  Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.

Authors:  W S Griffin; L C Stanley; C Ling; L White; V MacLeod; L J Perrot; C L White; C Araoz
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

View more
  7 in total

1.  The design and delivery of a thermally responsive peptide to inhibit S100B-mediated neurodegeneration.

Authors:  S M Hearst; L R Walker; Q Shao; M Lopez; D Raucher; P J S Vig
Journal:  Neuroscience       Date:  2011-09-17       Impact factor: 3.590

2.  A unique downregulation of h2-calponin gene expression in Down syndrome: a possible attenuation mechanism for fetal survival by methylation at the CpG island in the trisomic chromosome 21.

Authors:  J Kuromitsu; H Yamashita; H Kataoka; T Takahara; M Muramatsu; T Sekine; N Okamoto; Y Furuichi; Y Hayashizaki
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

3.  Glial S100B protein modulates mutant ataxin-1 aggregation and toxicity: TRTK12 peptide, a potential candidate for SCA1 therapy.

Authors:  Parminder J S Vig; Scoty Hearst; Qingmei Shao; Mariper E Lopez; Henry A Murphy; Eshan Safaya
Journal:  Cerebellum       Date:  2011-06       Impact factor: 3.847

4.  Bergmann glial S100B activates myo-inositol monophosphatase 1 and Co-localizes to purkinje cell vacuoles in SCA1 transgenic mice.

Authors:  Parminder J S Vig; Qingmei Shao; S H Subramony; Mariper E Lopez; Eshan Safaya
Journal:  Cerebellum       Date:  2009-07-11       Impact factor: 3.847

5.  Glial S100B Positive Vacuoles In Purkinje Cells: Earliest Morphological Abnormality In SCA1 Transgenic Mice.

Authors:  Parminder J S Vig; Maripar E Lopez; Jinrong Wei; David R D'Souza; Sh Subramony; Jeffrey Henegar; Jonathan D Fratkin
Journal:  J Neurol Sci Turk       Date:  2006

6.  Concentrations of several proteins characteristic of nervous tissue in cerebral cortex of patients with Alzheimer's disease.

Authors:  K Kato; N Kurobe; F Suzuki; R Morishita; T Asano; T Sato; T Inagaki
Journal:  J Mol Neurosci       Date:  1991       Impact factor: 3.444

7.  Comparison of calbindin D-28k and S-100 protein B in neuroblastoma as determined by enzyme immunoassay.

Authors:  Y Ishiguro; K Kato; H Akatsuka; H Iwata; F Ito; Y Watanabe; M Nagaya
Journal:  Jpn J Cancer Res       Date:  1996-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.